RE:I must Admit..If much of their covid revenues comes from movie productions, then expect seasonality swings in those revenues. There are slow times in movie productions and there are busy times. Busy times are upon us again for the fall.
What I find interesting is that people keep saying that the share price is low because the market is not factoring in their covid revenues, but in the same breath we have the same people and a few different one saying the share price is low because their covid revenues were down in the second quarter. So what is the case here, are we counting those revenues or not, you can't have it both ways.
The reality is this company is currently on target for a $60 million run rate for the year. That makes this stock's share price extremely undervalued. Even with just the current cash in the bank and giving that 10x puts this stock at $0.28, but a $60 million revenue runrate puts it at $1.69 and the current $30 million puts it at $0.84. Revenue is still revenue and I get their main focus is AI. However, covid testing is not going anywhere, the company is debt free and all that extra cash keeps strengthening this company, yet the stock price continues to remain low or even just slightly higher than where it was one year ago. Can someone honestly tell me that the company deserves a share price nearly equal to where it was one year ago. Financially this company is sitting in a far better position, with continued revenues, not debt, growth in their AI and expansion.